Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya H Buch

Showing results (11-20 of 180) with videos related to

Pageof 18
Sort By:
RMD Open|July 27, 2022
'Difficult to treat' rheumatoid arthritis: current position and considerations for next stepsYvonne Tan, Maya H Buch
Nature Reviews. Rheumatology|December 9, 2020
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritisMaya H Buch, Stephen Eyre, Dennis McGonagle
Drug, Healthcare and Patient Safety|June 25, 2011
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerationsSarah Horton, Maya H Buch, Paul Emery
Expert Opinion on Biological Therapy|March 22, 2018
GP2015 as a promising therapy for rheumatoid arthritisJohn Fitton, Alessandro Giollo, Maya H Buch
Rheumatology (Oxford, England)|October 19, 2021
Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the 'VEDERA' trialRudresh Shukla, Paul Emery, Maya H Buch
Clinical and Experimental Rheumatology|August 28, 2018
Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trialsMaya H Buch, Alyssa Johnsen, Michael Schiff
Annals of the Rheumatic Diseases|July 15, 2019
'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients'Maya H Buch, Andrew Melville, Dennis G McGonagle
Expert Opinion on Drug Safety|June 7, 2018
Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a reviewAlessandro Giollo, Lesley-Anne Bissell, Maya H Buch
Autoimmunity Reviews|November 1, 2011
To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50Maya H Buch, Andrea Rubbert-Roth, Gianfranco Ferraccioli
Nature Reviews. Rheumatology|June 2, 2017
Biologics registers in RA: methodological aspects, current role and future applicationsElena Nikiphorou, Maya H Buch, Kimme L Hyrich
Pageof 18

Showing results (11-20 of 180) with videos related to

Sort By:
Pageof 18
RMD Open|July 27, 2022
'Difficult to treat' rheumatoid arthritis: current position and considerations for next stepsYvonne Tan, Maya H Buch
Nature Reviews. Rheumatology|December 9, 2020
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritisMaya H Buch, Stephen Eyre, Dennis McGonagle
Drug, Healthcare and Patient Safety|June 25, 2011
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerationsSarah Horton, Maya H Buch, Paul Emery
Expert Opinion on Biological Therapy|March 22, 2018
GP2015 as a promising therapy for rheumatoid arthritisJohn Fitton, Alessandro Giollo, Maya H Buch
Rheumatology (Oxford, England)|October 19, 2021
Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the 'VEDERA' trialRudresh Shukla, Paul Emery, Maya H Buch
Clinical and Experimental Rheumatology|August 28, 2018
Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trialsMaya H Buch, Alyssa Johnsen, Michael Schiff
Annals of the Rheumatic Diseases|July 15, 2019
'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients'Maya H Buch, Andrew Melville, Dennis G McGonagle
Expert Opinion on Drug Safety|June 7, 2018
Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a reviewAlessandro Giollo, Lesley-Anne Bissell, Maya H Buch
Autoimmunity Reviews|November 1, 2011
To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50Maya H Buch, Andrea Rubbert-Roth, Gianfranco Ferraccioli
Nature Reviews. Rheumatology|June 2, 2017
Biologics registers in RA: methodological aspects, current role and future applicationsElena Nikiphorou, Maya H Buch, Kimme L Hyrich
Pageof 18